
The CEO of Novo Nordisk, Lars Fruergaard Jørgensen, is satisfied with the sales growth in the first half of 2024, he says in the semi-annual report. (Archive photo). Photo: Mads Claus Rasmussen/Ritzau Scanpix
Novo Nordisk gains 20 billion profit
Novo Nordisk, a Danish pharmaceutical giant, has earned a profit of 20.1 billion Danish kroner in the second quarter, a 3% increase from the same period last year. The growth is primarily driven by the popular diabetes treatment Ozempic and the obesity treatment Wegovy. The company’s sales...
Get full access to Danish News in English
Gain exclusive access to daily news updates in English pertaining to Denmark with a Ritzau News subscription.
Already a subscriber?